NCT03030378: Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors

NCT03030378
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Known, active and untreated brain metastases and/or carcinomatous meningitis- see trial for details
https://ClinicalTrials.gov/show/NCT03030378

Comments are closed.

Up ↑